Mohammed Sabri1, Jinglu Ai, R Loch Macdonald. 1. Division of Neurosurgery, St Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8.
Abstract
BACKGROUND AND PURPOSE: Endothelin receptor antagonists such as clazosentan decrease large-artery vasospasm after experimental and clinical subarachnoid hemorrhage. We used clazosentan to gain insight into the pathophysiology of subarachnoid hemorrhage by determining if decreasing vasospasm is associated with alleviation of other secondary complications of subarachnoid hemorrhage such as oxidative stress, endothelial nitric oxide synthase dysfunction, microthromboembolism, and neuronal injury. METHODS: Mice were subjected to subarachnoid hemorrhage by injection of blood into the chiasmatic cistern. They were treated with clazosentan or vehicle by continuous intraperitoneal infusion for 48 hours. Middle cerebral artery vasospasm, superoxide anion radical, peroxynitrite, microthromboemboli, endothelial nitric oxide synthase uncoupling, cerebral blood flow, neuronal injury, and mortality were assessed. RESULTS: Clazosentan preserved cerebral blood flow, alleviated vasospasm, and decreased mortality but did not affect superoxide anion radical, peroxynitrite, or microthromboemboli in the brain. Endothelial nitric oxide synthase uncoupling and neuronal injury also were not reduced by clazosentan. CONCLUSIONS: This study shows large-artery vasospasm is pathophysiologically independent of some other effects of subarachnoid hemorrhage. The findings have implications for development of treatments for this disease.
BACKGROUND AND PURPOSE: Endothelin receptor antagonists such as clazosentan decrease large-artery vasospasm after experimental and clinical subarachnoid hemorrhage. We used clazosentan to gain insight into the pathophysiology of subarachnoid hemorrhage by determining if decreasing vasospasm is associated with alleviation of other secondary complications of subarachnoid hemorrhage such as oxidative stress, endothelial nitric oxide synthase dysfunction, microthromboembolism, and neuronal injury. METHODS:Mice were subjected to subarachnoid hemorrhage by injection of blood into the chiasmatic cistern. They were treated with clazosentan or vehicle by continuous intraperitoneal infusion for 48 hours. Middle cerebral artery vasospasm, superoxide anion radical, peroxynitrite, microthromboemboli, endothelial nitric oxide synthase uncoupling, cerebral blood flow, neuronal injury, and mortality were assessed. RESULTS:Clazosentan preserved cerebral blood flow, alleviated vasospasm, and decreased mortality but did not affect superoxide anion radical, peroxynitrite, or microthromboemboli in the brain. Endothelial nitric oxide synthase uncoupling and neuronal injury also were not reduced by clazosentan. CONCLUSIONS: This study shows large-artery vasospasm is pathophysiologically independent of some other effects of subarachnoid hemorrhage. The findings have implications for development of treatments for this disease.
Authors: Daniel Hänggi; Nima Etminan; Hans Jakob Steiger; Mark Johnson; M Melissa Peet; Tom Tice; Kevin Burton; Bruce Hudson; Michele Turner; Angela Stella; Parissa Heshmati; Cara Davis; Herbert J Faleck; R Loch Macdonald Journal: Neurotherapeutics Date: 2016-04 Impact factor: 7.620
Authors: Mutsumi Fujii; Junhao Yan; William B Rolland; Yoshiteru Soejima; Basak Caner; John H Zhang Journal: Transl Stroke Res Date: 2013-08 Impact factor: 6.829
Authors: Kamil G Laban; Mervyn D I Vergouwen; Rick M Dijkhuizen; Emily S Sena; Malcolm R Macleod; Gabriel J E Rinkel; H Bart van der Worp Journal: J Cereb Blood Flow Metab Date: 2015-05-06 Impact factor: 6.200